Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Issue 5 (22nd August 2014)

• Record Type: Journal Article
• Authors: Duits, Flora H.; Prins, Niels D.; Lemstra, Afina W.; Pijnenburg, Yolande A.L.; Bouwman, Femke H.; Teunissen, Charlotte E.; Scheltens, Philip; van der Flier, Wiesje M.
• Is Part Of: Alzheimer's & dementia. Volume 11:Issue 5(2015)
• Page Start: 523
• Page End: 532
• Publication Date: 2014-08-22
• Subjects: Dementia -- Alzheimer's disease -- Clinical practice -- Diagnostic impact -- Assessment of cognitive disorders -- Cerebrospinal fluid -- Amyloid-β1–42 -- Tau -- Biomarkers; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2014.05.1753
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: We aimed to assess the impact of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease on decision making and patient management in a tertiary memory clinic. Methods: We included all patients, for 1 year, visiting the VUmc Alzheimer Center for cognitive screening. Neurologists completed questionnaires before and after CSF disclosure. We assessed the change of diagnosis, diagnostic confidence, and impact on patient management. Results: A total of 438 patients (age 63 ± 8 years, 39% women) were included, of whom 351 (80%) underwent lumbar puncture. After the disclosure of CSF 23/351 diagnoses (7%) were changed. Diagnostic confidence increased from 84% to 89% ( P < .001). There were consequences for management in 44/351 patients (13%) with CSF, and 13/87 patients (15%) because of unavailable CSF. There was no effect of age on these results. Conclusions: CSF biomarkers aid clinicians with decision making during diagnostic work‐up of cognitive disorders. This study may be useful for developing guidelines for the implementation of CSF biomarkers in daily practice.